Namenda and Lunesta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Namenda and Lunesta. Common interactions include meningitis viral among females and fall among males.

The phase IV clinical study analyzes what interactions people who take Namenda and Lunesta have. It is created by eHealthMe based on reports of 82 people who take Namenda and Lunesta from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

82 people who take Namenda and Lunesta together, and have interactions are studied.

What is Namenda?

Namenda has active ingredients of memantine hydrochloride. It is often used in dementia. eHealthMe is studying from 13,744 Namenda users for its effectiveness, alternative drugs and more.

What is Lunesta?

Lunesta has active ingredients of eszopiclone. It is often used in insomnia. eHealthMe is studying from 25,595 Lunesta users for its effectiveness, alternative drugs and more.

Number of Namenda and Lunesta reports submitted per year:

Common Namenda and Lunesta drug interactions by gender *:

female:

Meningitis viral
Type 2 diabetes mellitus
Urinary tract infection
Asthenia
Cardiac failure congestive
Constipation
Depression
Diarrhoea
Diastolic dysfunction
Dysstasia

male:

Fall
Hyperhidrosis
Aggression
Blood pressure increased
Confusional state
Dry mouth
Hallucination
Heart rate increased
Bipolar disorder
Blood insulin increased

Common Namenda and Lunesta drug interactions by age *:

0-1:

Blood cholesterol increased
Blood triglycerides increased
Hyperprolactinaemia
Leiomyoma
Obesity
Osteoarthritis
Patellofemoral pain syndrome
Stress fracture
Type 2 diabetes mellitus

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Acanthosis
Arthralgia
Asthma
Blood cholesterol increased
Blood triglycerides increased
Chest pain
Constipation
Convulsion
Dyspnoea
Fracture

40-49:

n/a

50-59:

Renal impairment
Respiratory arrest
Upper respiratory tract infection
Aphasia
Asthenia
Cardiac disorder
Cerebrovascular accident
Cold sweat
Drug administration error
Drug effect delayed

60+:

Confusional state
Catatonia
Abnormal behaviour
Aggression
Disorientation
Drug ineffective
Encephalitis
General physical health deterioration
Hip fracture
Meningitis viral

Common conditions people have *:

Depression: 11 people, 13.41%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 9 people, 10.98%
Parkinson's Disease: 8 people, 9.76%
Pain: 8 people, 9.76%
Stress And Anxiety: 7 people, 8.54%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 6 people, 7.32%
High Blood Pressure: 6 people, 7.32%
High Blood Cholesterol: 6 people, 7.32%
Type 2 Diabetes: 5 people, 6.10%
Psychotic Disorder: 5 people, 6.10%

* Approximation only. Some reports may have incomplete information.

Do you take Namenda and Lunesta?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Lai SW, Lai HC, Lin CL, Liao KF, "Zopiclone use associated with increased risk of acute pancreatitis: a case–control study in Taiwan", International journal of clinical practice, 2015 Nov .